Cationic microparticles are a potent delivery system for a HCV DNA vaccine

Vaccine

Volumn 23, Issue 5, 2004, Pages 672-680

  O'Hagan, Derek T ^a   Singh, Manmohan ^a   Dong, Christine ^a   Ugozzoli, Mildred ^a   Berger, Kim ^a   Glazer, Edward ^a   Selby, Mark ^b   Wininger, Mark ^a   Ng, Philip ^a   Crawford, Kevin ^a   Paliard, Xavier ^c   Coates, Steven ^a   Houghton, Michael ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Medarex   (United States)

^c Gryphon Therapeutics   (United States)

Author keywords

DNA vaccine; HCV vaccine; PLG microparticles

Indexed keywords

DNA VACCINE; HEPATITIS C VACCINE; IMMUNOLOGICAL ADJUVANT; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NAKED DNA; POLYGLACTIN; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN; WATER OIL CREAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RHESUS MONKEY; SEROCONVERSION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CATIONS; CYTOTOXICITY TESTS, IMMUNOLOGIC; DNA, VIRAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HEPATITIS C; HEPATITIS C ANTIBODIES; IMMUNOGLOBULIN G; LACTIC ACID; MACACA MULATTA; MICE; MICROSPHERES; PLASMIDS; POLYGLYCOLIC ACID; POLYMERS; POLYSORBATES; SQUALENE; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES;

EID: 20844448215     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.06.037     Document Type: Article

References (44)

1. Q.L. Choo, G. Kuo, A.J. Weiner, L.R. Overby, D.W. Bradley, and M. Houghton Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 4902 1989 359 362
2. G.L. Armstrong, M.J. Alter, G.M. McQuillan, and H.S. Margolis The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States Hepatology 31 3 2000 777 782
3. J. Cohen The scientific challenge of hepatitis C Science 285 5424 1999 26 30
4. M.J. Alter The detection, transmission, and outcome of hepatitis C virus infection Infect. Agents Dis. 2 3 1993 155 166
5. M.J. Alter Hepatitis C virus infection in the United States J. Hepatol 31 Suppl. 1 1999 88 91
6. J.E. Everhart, M. Stolar, and J.H. Hoofnagle Management of hepatitis C: a national survey of gastroenterologists and hepatologists Hepatology 26 3(Suppl. 1) 1997 78S 82S
7. H.J. Alter, and L.B. Seeff Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome Semin. Liver Dis. 20 1 2000 17 35
8. T. Poynard, P. Marcellin, and S.S. Lee Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus International Hepatitis Interventional Therapy Group (IHIT) Lancet 352 9138 1998 1426 1432
9. J.G. McHutchison, S.C. Gordon, and E.R. Schiff Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C Hepatitis Interventional Therapy Group N. Engl. J. Med. 339 21 1998 1485 1492
10. H.M. Diepolder, R. Zachoval, and R.M. Hoffmann Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection Lancet 346 8981 1995 1006 1007
11. G. Missale, R. Bertoni, and V. Lamonaca Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response J. Clin. Invest. 98 3 1996 706 714
12. S. Cooper, A.L. Erickson, and E.J. Adams Analysis of a successful immune response against hepatitis C virus Immunity 10 4 1999 439 449
13. F. Lechner, D.K. Wong, and P.R. Dunbar Analysis of successful immune responses in persons infected with hepatitis C virus J. Exp. Med. 191 9 2000 1499 1512
14. S.L. Tsai, Y.F. Liaw, M.H. Chen, C.Y. Huang, and G.C. Kuo Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity Hepatology 25 2 1997 449 458
15. D.R. Nelson, C.G. Marousis, and G.L. Davis The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C J. Immunol. 158 3 1997 1473 1481
16. M.E. Major, K. Mihalik, and M. Puig Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge J. Virol. 76 13 2002 6586 6595
17. Q.L. Choo, G. Kuo, and R. Ralston Vaccination of chimpanzees against infection by the hepatitis C virus Proc. Natl. Acad. Sci. U.S.A. 91 4 1994 1294 1298
18. K. Ishii, D. Rosa, and Y. Watanabe High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C Hepatology 28 4 1998 1117 1120
19. K. Krawczynski, M.J. Alter, and D.L. Tankersley Effect of immune globulin on the prevention of experimental hepatitis C virus infection J. Infect. Dis. 173 4 1996 822 828
20. C. Feray, M. Gigou, and D. Samuel Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation Ann. Intern. Med. 128 10 1998 810 816
21. R.G. Knodell, M.E. Conrad, A.L. Ginsberg, and C.J. Bell Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis Lancet 1 7959 1976 557 561
22. R.G. Knodell, M.E. Conrad, and K.G. Ishak Development of chronic liver disease after acute non-A, non-B post-transfusion hepatitis Role of gamma-globulin prophylaxis in its prevention Gastroenterology 72 5(Pt 1) 1977 902 909
23. M. Piazza, L. Sagliocca, and G. Tosone Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin A randomized controlled trial Arch. Intern. Med. 157 14 1997 1537 1544
24. S. Gurunathan, D.M. Klinman, and R.A. Seder DNA vaccines: immunology, application, and optimization Annu. Rev. Immunol. 18 2000 927 974
25. R. Wang, D.L. Doolan, and T.P. Le Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine Science 282 5388 1998 476 480
26. T.P. Le, K.M. Coonan, and R.C. Hedstrom Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers Vaccine 18 18 2000 1893 1901
27. J.E. Epstein, E.J. Gorak, and Y. Charoenvit Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes Hum. Gene Ther. 13 13 2002 1551 1560
28. M. Singh, M. Briones, G. Ott, and D. O'Hagan Cationic microparticles: a potent delivery system for DNA vaccines Proc. Natl. Acad. Sci. U.S.A. 97 2 2000 811 816
29. M. Briones, M. Singh, and M. Ugozzoli The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery Pharm. Res. 18 5 2001 709 711
30. D. O'Hagan, M. Singh, and M. Ugozzoli Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines J. Virol. 75 19 2001 9037 9043
31. J. zur Megede, M.C. Chen, and B. Doe Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene J. Virol. 74 6 2000 2628 2635
32. G. Ott, G.L. Barchfeld, D. Chernoff, R. Radhakrishnan, P. van Hoogevest, and G. Van Nest MF59: design and evaluation of a safe and potent adjuvant for human vaccines M.F. Powell M.J. Newman Vaccine design: the subunit and adjuvant approach 1995 Plenum Press New York 277 296
33. G. Ott, R. Radhakrishnan, J.-H. Fang, and M. Hora The adjuvant MF59: a 10-year perspective D.T. O'Hagan Vaccine adjuvants: preparation methods and research protocols. 2000 Humana Press Totowa, NJ 211 228
34. R.R. Spaete, D. Alexander, and M.E. Rugroden Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells Virology 188 2 1992 819 830
35. M.K. Song, S.W. Lee, Y.S. Suh, K.J. Lee, and Y.C. Sung Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice J. Virol. 74 6 2000 2920 2925
36. G. Widera, M. Austin, and D. Rabussay Increased DNA vaccine delivery and immunogenicity by electroporation in vivo J. Immunol. 164 9 2000 4635 4640
37. R. Ralston, K. Thudium, and K. Berger Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses J. Virol. 67 11 1993 6753 6761
38. A. Op De Beeck, R. Montserret, and S. Duvet The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization J. Biol. Chem. 275 40 2000 31428 31437
39. S.W. Barnett, S. Rajasekar, and H. Legg Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit Vaccine 15 8 1997 869 873
40. M. Dupuis, K. Denis-Mize, and C. Woo Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice J. Immunol. 165 5 2000 2850 2858
41. J.M. Heile, Y.L. Fong, and D. Rosa Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates J. Virol. 74 15 2000 6885 6892
42. N.K. Polakos, D. Drane, and J. Cox Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine J. Immunol. 166 5 2001 3589 3598
43. M. Singh, and D. O'Hagan Advances in vaccine adjuvants Nat. Biotechnol. 17 11 1999 1075 1081
44. K.S. Denis-Mize, M. Dupuis, and M.L. MacKichan Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells Gene Ther. 7 24 2000 2105 2112